See more : Entasis Therapeutics Holdings Inc. (ETTX) Income Statement Analysis – Financial Results
Complete financial analysis of Theralase Technologies Inc. (TLTFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theralase Technologies Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Kaufman & Broad S.A. (KOF.PA) Income Statement Analysis – Financial Results
- Tyler Technologies, Inc. (TYL) Income Statement Analysis – Financial Results
- Paradise Co., Ltd. (034230.KQ) Income Statement Analysis – Financial Results
- Shanghai Anoky Group Co., Ltd (300067.SZ) Income Statement Analysis – Financial Results
- Quaterra Resources Inc. (QTRRF) Income Statement Analysis – Financial Results
Theralase Technologies Inc. (TLTFF)
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07M | 1.14M | 780.64K | 929.12K | 964.05K | 1.73M | 2.34M | 1.92M | 1.95M | 1.38M | 1.20M | 1.82M | 2.03M | 2.04M | 2.36M | 2.17M | 1.56M | 1.44M | 1.21M | 657.35K | 27.72K | 2.38K | 0.00 |
| Cost of Revenue | 508.17K | 510.40K | 470.70K | 659.44K | 903.30K | 786.43K | 945.01K | 796.57K | 629.61K | 459.32K | 404.54K | 575.16K | 639.61K | 668.04K | 799.73K | 688.94K | 396.51K | 368.62K | 297.28K | 176.96K | 15.61K | 0.00 | 0.00 |
| Gross Profit | 562.13K | 628.17K | 309.94K | 269.68K | 60.76K | 947.64K | 1.40M | 1.12M | 1.32M | 921.28K | 799.08K | 1.25M | 1.39M | 1.37M | 1.56M | 1.48M | 1.16M | 1.07M | 909.63K | 480.39K | 12.12K | 2.38K | 0.00 |
| Gross Profit Ratio | 52.52% | 55.17% | 39.70% | 29.03% | 6.30% | 54.65% | 59.66% | 58.49% | 67.63% | 66.73% | 66.39% | 68.47% | 68.45% | 67.26% | 66.11% | 68.23% | 74.58% | 74.35% | 75.37% | 73.08% | 43.71% | 100.00% | 0.00% |
| Research & Development | 3.13M | 4.28M | 2.92M | 3.45M | 4.16M | 1.70M | 2.65M | 1.87M | 3.03M | 1.46M | 527.23K | 873.34K | 759.35K | 547.99K | 164.18K | 226.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.03M | 1.44M | 1.75M | 2.02M | 2.53M | 1.70M | 2.86M | 2.52M | 2.42M | 1.43M | 924.35K | 1.23M | 1.87M | 1.26M | 992.74K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.19K | 88.24K | 96.83K | 447.88K | 716.34K | 871.41K | 1.92M | 1.61M | 1.09M | 598.18K | 433.62K | 626.38K | 197.24K | 662.06K | 476.42K | 633.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.13M | 1.53M | 1.85M | 2.47M | 3.25M | 2.57M | 4.78M | 4.13M | 3.51M | 2.03M | 1.36M | 1.86M | 2.07M | 1.92M | 1.47M | 1.97M | 2.09M | 1.19M | 785.57K | 398.73K | 62.88K | 50.74K | 47.09K |
| Other Expenses | -4.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 747.00 | -6.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -28.00 | 2.93K | -2.00 | 342.92K |
| Operating Expenses | 562.13K | 5.86M | 4.85M | 5.97M | 7.48M | 4.31M | 7.48M | 6.03M | 6.57M | 3.50M | 1.90M | 2.74M | 2.85M | 2.58M | 1.80M | 2.39M | 2.26M | 1.36M | 897.63K | 417.08K | 64.29K | 50.74K | 51.07K |
| Cost & Expenses | 5.82M | 6.37M | 5.32M | 6.63M | 8.38M | 5.10M | 8.43M | 6.83M | 7.20M | 3.96M | 2.31M | 3.31M | 3.49M | 3.24M | 2.60M | 3.08M | 2.65M | 1.73M | 1.19M | 594.04K | 79.90K | 50.74K | 51.07K |
| Interest Income | 49.81K | 30.66K | 22.66K | 103.69K | 33.60K | 18.63K | 6.61K | 15.43K | 37.17K | 8.42K | 8.48K | 13.12K | 11.67K | 5.66K | 5.87K | 9.84K | 9.51K | 11.23K | 9.06K | 6.07K | 1.99K | 2.38K | 5.60K |
| Interest Expense | 30.41K | 21.25K | 5.34K | 9.68K | 12.36K | 663.00 | 87.00 | 198.00 | 795.00 | 19.54K | 42.77K | 23.00K | 5.77K | 2.25K | 5.62K | 10.33K | 4.53K | 5.33K | 8.17K | 8.44K | 882.00 | 13.00 | 18.42K |
| Depreciation & Amortization | 286.12K | 313.23K | 276.15K | 272.28K | 255.26K | 222.93K | 253.93K | 149.30K | 135.00K | 82.89K | 77.45K | 48.80K | 55.30K | 103.86K | 175.58K | 179.26K | 167.46K | 164.59K | 112.07K | 18.35K | 1.42K | -96.72K | -102.14K |
| EBITDA | -4.25M | -4.90M | -4.24M | -5.32M | -7.15M | -3.13M | -5.84M | -4.77M | -5.07M | -2.49M | -1.03M | -1.44M | -1.41M | -1.06M | -66.25K | -733.12K | -926.94K | -123.30K | 124.06K | 81.66K | -50.76K | -48.36K | 403.03K |
| EBITDA Ratio | -397.49% | -429.28% | -543.49% | -572.66% | -739.72% | -180.25% | -248.63% | -247.12% | -261.16% | -180.33% | -84.57% | -78.25% | -69.33% | -53.87% | -2.81% | -24.64% | -59.42% | -8.58% | 10.28% | 12.66% | -177.67% | -1,981.14% | 0.00% |
| Operating Income | -4.75M | -5.20M | -4.52M | -5.59M | -7.39M | -3.35M | -6.08M | 4.92M | 5.21M | 2.58M | 1.10M | 1.51M | -1.46M | 1.20M | 241.83K | 1.11M | 1.09M | 287.89K | 12.00K | 61.75K | 53.69K | 49.67K | 505.18K |
| Operating Income Ratio | -443.51% | -456.79% | -578.87% | -601.97% | -766.20% | -193.11% | -259.47% | 256.46% | 267.74% | 186.62% | 91.71% | 82.75% | -72.06% | 58.96% | 10.25% | 51.24% | 70.16% | 20.03% | 0.99% | 9.39% | 193.65% | 2,091.28% | 0.00% |
| Total Other Income/Expenses | 176.09K | -3.76K | 130.48K | 98.17K | -16.69K | 10.36K | -8.85K | 185.44K | 344.27K | 166.48K | -48.37K | -3.02M | 747.00 | -1.20M | -241.83K | -1.11M | -2.21M | -569.89K | 895.00 | -2.40K | -53.69K | -1.31K | -111.19K |
| Income Before Tax | -4.57M | -5.24M | -4.41M | -5.60M | -7.41M | -3.36M | -6.09M | -4.92M | -5.21M | -2.59M | -1.15M | -1.51M | -1.46M | 1.20M | 0.00 | 912.38K | -1.11M | -282.00K | 12.89K | 59.34K | 55.10K | 48.36K | 393.99K |
| Income Before Tax Ratio | -427.06% | -459.81% | -565.06% | -602.56% | -769.04% | -193.58% | -260.13% | -256.46% | -267.74% | -187.42% | -95.73% | -82.75% | -72.02% | 58.66% | 0.00% | 42.08% | -71.38% | -19.62% | 1.07% | 9.03% | 198.77% | 2,036.13% | 0.00% |
| Income Tax Expense | 0.00 | 21.25K | 5.34K | 9.68K | 12.36K | 663.00 | 87.00 | 198.00 | 794.00 | 19.54K | 42.77K | 23.00K | -5.90K | -3.40K | -251.00 | 199.29K | -4.98K | -575.79K | 0.00 | 3.94K | 399.00 | 98.04K | 569.06K |
| Net Income | -4.57M | -5.24M | -4.41M | -5.60M | -7.41M | -3.36M | -6.09M | -4.92M | -5.21M | -2.59M | -1.15M | -1.51M | -1.45M | -1.20M | -241.58K | -1.11M | -1.11M | -282.00K | 12.89K | 59.34K | -49.65K | -49.68K | -175.08K |
| Net Income Ratio | -427.06% | -459.81% | -565.06% | -602.56% | -769.04% | -193.58% | -260.13% | -256.46% | -267.74% | -187.42% | -95.73% | -82.75% | -71.73% | -58.79% | -10.24% | -51.27% | -71.38% | -19.62% | 1.07% | 9.03% | -179.11% | -2,091.92% | 0.00% |
| EPS | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.03 | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.03 | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 219.98M | 207.92M | 204.28M | 204.28M | 144.68M | 130.49M | 124.09M | 109.04M | 95.96M | 74.98M | 47.85M | 43.82M | 40.62M | 39.20M | 35.35M | 34.94M | 34.94M | 33.24M | 33.09M | 26.97M | 21.09M | 20.66M | 20.66M |
| Weighted Avg Shares Out (Dil) | 219.97M | 207.92M | 204.28M | 204.28M | 144.68M | 130.49M | 124.09M | 109.04M | 95.96M | 74.98M | 47.85M | 43.82M | 40.62M | 39.20M | 35.35M | 34.94M | 34.94M | 33.24M | 33.09M | 27.92M | 21.09M | 20.66M | 20.66M |
Theralase to present data from Phase 2 bladder cancer study at Advisory Board meetings
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it will be hosting Advisory Board meetings at two upcoming urologic community forums to present data from its Phase 2 bladder cancer study. The Phase 2 clinical study, known as Study 2, provides a...
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations,...
Theralase Technologies donates two lasers to aid landmark Parkinson's trial
Theralase Technologies Inc, a clinical-stage pharma company focused on photo-dynamic compounds, has donated two of its pioneering TLC-2400 Cool Laser Therapy (CLT) systems to the University of Windsor to aid the search for a breakthrough in Parkinson's disease. In a collaborative effort with the...
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe...
Theralase Technologies brings on Dr. Michael Jewett to consult on Phase 2 bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that Dr. Michael Jewett has joined the company as an independent consultant to assist it in completing patient enrollment for its Phase 2 clinical study evaluating its photodynamic therapy technology for Bacillus Calmette-Guérin-unresponsive non...
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe...
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe...
Theralase is making personalized cancer treatment a reality
A new treatment for bladder cancer could offer a higher quality of life for patients for an extended period of time compared to existing therapies. Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF), a Canadian pharmaceutical company, is in the midst of a...
Theralase provides encouraging interim results for Phase II study on bladder cancer treatment
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has released interim clinical data for its Phase II non-muscle invasive bladder cancer study indicating complete response rates exceeding International Bladder Cancer Group recommendations at various time points. The study, designed to evaluate the safety...
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation...
Source: https://incomestatements.info
Category: Stock Reports